secwatch.observer — SEC 8-K summary
======================================

Issuer:     TuHURA Biosciences, Inc./NV (HURA)
CIK:        0001498382
Form:       8-K
Filed at:   2026-04-01T23:59:59+00:00
Accession:  0001193125-26-135766
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TuHURA FY2025 cash $3.6M, R&D $20.5M; Phase 3 MCC trial ongoing; Kineta acquired
--------------------------------------------------------------------------------

- Cash $3.6M at Dec 31, 2025; additional $7.5M from 2025 registered direct offering received Q1 2026.
- R&D expenses $20.5M for FY2025 vs $14.7M in FY2024; operating cash outflow $27.7M.
- Phase 3 trial of IFx-2.0 in Merkel cell carcinoma initiated under FDA SPA; enrollment estimated to complete mid-2027.
- Closed $10.5M acquisition of Kineta, gaining VISTA antibody TBS-2025; $21.2M raised in 2025 offerings.
- Upcoming milestones: FDA meeting for TBS-2025 in June 2026; ADC lead selection in 1H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1498382/000119312526135766/0001193125-26-135766-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1498382/000119312526135766/hura-20260401.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-135766

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer